azacitidin sandoz 25 mg/ml prašak za suspenziju za injekciju
sandoz d.o.o., maksimirska 120, zagreb, hrvatska - azacitidin - prašak za suspenziju za injekciju - 25 mg/ml - urbroj: svaka bočica s praškom sadrži 100 mg azacitidina, nakon rekonstitucije jedan ml suspenzije sadrži 25 mg azacitidina
azacitidin stada 25 mg/ml prašak za suspenziju za injekciju
stada d.o.o., hercegovačka 14, zagreb, hrvatska - azacitidin - prašak za suspenziju za injekciju - 25 mg/ml - urbroj: svaka bočica sadrži 100 mg azacitidina, nakon rekonstitucije svaki ml suspenzije sadrži 25 mg azacitidina
vidaculem 25 mg/ml prašak za suspenziju za injekciju
onkogen kft., becsi ut 77-79, budimpešta, mađarska - azacitidin - prašak za suspenziju za injekciju - urbroj: svaka bočica sadrži 100 mg azacitidina. nakon rekonstitucije s 4 ml vode za injekcije, svaki ml suspenzije sadrži 25 mg azacitidina.
azacitidin stada 100 mg/1 bočica prašak za suspenziju za injekciju
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - azacitidin - prašak za suspenziju za injekciju - 100 mg/1 bočica - 1 bočica sa praškom za suspenziju za injekciju sadrži: 100 mg azacitidina (nakon rekonstitucije svaki ml suspenzije sadrži 25 mg azacitidina)
vidaza 100 mg/1 bočica prašak za suspenziju za injekciju
amicus pharma d.o.o. - azacitidin - prašak za suspenziju za injekciju - 100 mg/1 bočica - 1 bočica sa praškom za suspenziju za injekciju sadrži: 100 mg azacitidina (nakon rekonstitucije svaki ml suspenzije sadrži 25 mg azacitidina)
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastična sredstva - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
scripta 25mg/ml prašak za suspenziju za injekciju
hemofarm a.d. vrŠac p.j. podgorica - azacitidin - prašak za suspenziju za injekciju - 25mg/ml
vidaza 100mg prašak za suspenziju za injekciju
"evropa lek pharma" doo podgorica - azacitidin - prašak za suspenziju za injekciju - 100mg
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
talira 100 mg/1 bočica prašak za suspenziju za injekciju
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - azacitidin - prašak za suspenziju za injekciju - 100 mg/1 bočica - 1 bočica sadrži 100 mg azacitidina